Abstract
In today’s competitive world, there are several strategies to deal with the fast changing environment, among which New product development (NPD) is a universal approach. Yet there is a risk that resources and labor spent on NPD products might fail. This concern is common in the pharmaceutical industry due to large investments, long development time, low success rate, and market uncertainty. Success factors in NPD are similar for the generic and bio-generic pharmaceutical industries. Out of 56 million deaths worldwide in 2004, cancer comprises 12%. Cancer had emerged as a major public health problem in developed and developing nation. At that time, there was a large and dynamic pipeline of products. The distribution of therapeutics in clinical trials across cancer types seems to correlate with the incidence of those cancer types (lung cancer, prostate cancer, Breast cancer and colorectal cancer) reasonably well, suggesting that the pharmaceutical industry is appropriately matching its resources to the size of the market. Chemotherapy is the predominant form of systemic treatment due to its targeted destruction of cancerous cells in any part of the body. However, its effectiveness is often hampered by the blood–brain barrier in cases of brain metastases. Depending on the requirement, it can be applied alone or in addition to other therapy systems like radiation therapy to specific metastatic sites. Specific breast and prostate cancers that are hormone-regulated and use the body hormones for development are often responsive to chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
